Tag: branded generics market overview

Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.

Branded Generics Market Size, Value And Growth Trajectory Through 2030

The branded generics market size has seen rapid expansion in recent years. It is forecast to rise from $393.5 billion in 2025 to $434.56 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 10.4%. The historical period’s growth can be attributed to factors such as patent expirations of key drugs, growing generic drug acceptance, rising healthcare expenditure, government support for generics, and the increasing prevalence of chronic diseases.

The branded generics market is projected to experience substantial expansion in the coming years, with its value anticipated to reach $653.17 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. This projected increase during the forecast period is attributable to several factors, including the broadening of branded generics product lines, the integration of digital marketing within the pharmaceutical sector, a rise in collaborations with healthcare providers, the expansion of emerging markets, and continuous improvements in drug formulation technologies. Key developments expected during this timeframe encompass enhanced brand recognition among patients, the implementation of distinctive marketing approaches, an increase in prescription volumes for branded generics, a growing inclination among physicians towards these products, and the ongoing enlargement of emerging markets for generic medications.

Get A Free Sample Report With In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Branded Generics Market Demand Drivers Opening New Revenue Streams

The increasing prevalence of chronic diseases is expected to fuel the expansion of the branded generics market. These are long-term health conditions that, while often not curable, can be managed and controlled. The rise in chronic diseases stems from factors such as increased use of tobacco products, insufficient nutrition, physical inactivity, excessive alcohol consumption, among others. Customers worldwide show a greater preference for branded generics to address chronic ailments, largely due to their affordability compared to standard medications. For instance, in April 2025, information from the Centers for Disease Control and Prevention, a US-based federal agency, indicated that in 2023, around 76.4% of U.S. adults reported experiencing at least one of 12 specified chronic conditions, and 51.4% of U.S. adults reported having multiple chronic conditions. Thus, the escalating occurrence of chronic diseases is a significant driver for the growth of the branded generics market.

Branded Generics Market Segment Analysis Spotlighting Growth Areas

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Branded Generics Market Trends Powering Strategic Industry Growth

Leading firms in branded generics are collaborating with pertinent entities to utilize shared resources and broaden their reach into fresh markets. As an illustration, in September 2024, Biocon Ltd., an India-based pharmaceutical company, formed a partnership with Tabuk Pharmaceuticals. Biocon will undertake the development and production of the GLP-1 products, guaranteeing premium biopharmaceuticals specifically designed for diabetes treatment. Tabuk Pharmaceuticals will possess the marketing authorization rights and oversee the registration, import, and promotion of these products throughout the Middle East, with a particular focus on Saudi Arabia. The agreement contains clauses for subsequent expansion into additional GLP products beyond the initial range, thereby facilitating a wider array of diabetes treatments. This collaboration seeks to provide distinct health solutions that improve patient well-being in Saudi Arabia and neighboring regions, consistent with both companies’ dedication to enhancing healthcare availability. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company, marketing both branded and generic pharmaceutical products.

Branded Generics Market Leading Companies: Who Holds The Strongest Market Presence?

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

View The Full Branded Generics Market Report:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Branded Generics Market Geographic Distribution And Regional Opportunities

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.

Branded Generics Market Expansion Outlook: What Revenue Opportunities Lie Ahead?

The branded generics sector has experienced significant expansion in recent years. Projections indicate an increase from $393.5 billion in 2025 to $434.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.4%. This historical growth has been driven by several factors, including key drug patent expirations, heightened acceptance of generic medications, increased healthcare spending, policy backing for generics from governments, and a rising incidence of chronic illnesses.

The branded generics market is projected to experience rapid expansion over the coming years, reaching an estimated $653.17 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.7%. This anticipated growth during the forecast period is fueled by several key factors, including the broadening of branded generics product lines, the increased utilization of digital marketing within the pharmaceutical industry, a rise in collaborations with healthcare providers, the expansion into developing markets, and progress in drug formulation technologies. Among the prominent trends set to shape the sector are a heightened level of brand recognition among patients, marketing campaigns that emphasize product differentiation, a surge in prescription volumes for branded generics, a growing preference among physicians for these drugs, and the further penetration of generic medications into emerging markets.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

#Branded Generics Market Growth Factors: Which Forces Are Supporting Market Expansion?

The anticipated expansion of the branded generics market is significantly fueled by the rising incidence of chronic diseases. These conditions are enduring ailments that typically lack a cure, yet they can be managed or treated effectively. A growing number of chronic disease cases are attributed to factors such as tobacco use, poor dietary habits, insufficient physical activity, and excessive alcohol consumption. Globally, consumers are increasingly turning to branded generics for managing these illnesses, as these medications offer a more affordable option compared to standard treatments. For example, in April 2025, data from the Centers for Disease Control and Prevention—a U.S. federal agency—revealed that in 2023, approximately 76.4% of American adults had at least one of twelve selected chronic conditions, with 51.4% experiencing multiple such conditions. Consequently, this upward trend in chronic disease prevalence is a key driver behind the growing branded generics market.

Branded Generics Market Segmentation Trends And Revenue Drivers

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Branded Generics Market Industry Trends: What Changes Are Reshaping Demand?

Major players in the branded generics sector are forming strategic alliances with relevant partners to pool resources and gain entry into fresh markets. As an illustration, in September 2024, Biocon Ltd., a pharmaceutical firm headquartered in India, joined forces with Tabuk Pharmaceuticals. Under this arrangement, Biocon is tasked with the development and production of GLP-1 products, guaranteeing top-tier biopharmaceuticals specifically designed to treat diabetes. Meanwhile, Tabuk Pharmaceuticals will assume the marketing authorization rights and oversee the registration, importation, and promotion of these products throughout the Middle East, with a particular emphasis on Saudi Arabia. The deal also encompasses provisions for extending into additional GLP products beyond the initial lineup, thereby enabling a wider spectrum of diabetes therapies. This collaboration is designed to provide distinctive healthcare solutions that improve patient well-being in Saudi Arabia and neighboring regions, reflecting the dedication of both entities to enhancing healthcare accessibility. Tabuk Pharmaceuticals, a Saudi Arabia-based drug company, offers both branded and generic pharmaceutical items.

Branded Generics Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Access The Complete Branded Generics Market Report:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Branded Generics Market Geographic Analysis: Where Is Demand Growing The Fastest?

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Market Size Is Forecasted For The Branded Generics Market By 2030 Based On Its 2026 Value?

The branded generics market has experienced substantial growth in recent years. Its value is anticipated to climb from $393.5 billion in 2025 to $434.56 billion in 2026, at a compound annual growth rate (CAGR) of 10.4%. This past expansion can be attributed to factors such as the expiration of patents for key drugs, increasing acceptance of generic medications, rising healthcare spending, government support for generics, and the growing prevalence of chronic diseases.

The branded generics market is anticipated to experience substantial expansion in the coming years. Its value is projected to reach $653.17 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.7%. This projected growth during the forecast period is primarily attributable to several factors, including the expanding range of branded generics, the increased integration of digital marketing within the pharmaceutical sector, a rise in collaborations with healthcare providers, the development of emerging markets, and continuous improvements in drug formulation technologies. Key trends anticipated over this period encompass a heightened awareness of brands among patients, the implementation of differentiated marketing approaches, an increase in the volume of prescriptions for branded generics, a growing inclination among physicians to prescribe branded generics, and the ongoing expansion of emerging markets for generic drugs.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which Growth Drivers Are Expected To Support The Branded Generics Market Forward?

The rising incidence of chronic diseases is anticipated to fuel the expansion of the branded generics market. Chronic diseases are persistent health conditions that are often incurable but manageable and controllable. Their increase stems from factors such as heightened tobacco use, insufficient nutrition, sedentary lifestyles, and excessive alcohol consumption, among others. Globally, consumers are favoring branded generics for managing chronic diseases due to their affordability compared to conventional medications. For instance, in April 2025, data from the Centers for Disease Control and Prevention, a US-based federal agency, indicated that in 2023, approximately 76.4% of U.S. adults reported experiencing at least one of 12 selected chronic conditions, with 51.4% of U.S. adults reporting multiple chronic conditions. Therefore, the growing prevalence of chronic diseases is a significant driver for the branded generics market’s growth.

How Is The Branded Generics Market Distributed Across Key Segments?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Which Trends Are Expected To Shape The Branded Generics Market?

Major companies in branded generics are establishing partnerships with relevant firms to pool resources and penetrate new markets. For instance, in September 2024, Biocon Ltd., an India-based pharmaceutical company, formed a partnership with Tabuk Pharmaceuticals. Biocon will be responsible for the development and manufacturing of the GLP-1 products, ensuring high-quality biopharmaceuticals crafted for diabetes treatment. Tabuk Pharmaceuticals will hold the marketing authorization rights and manage the registration, importation, and promotion of these products across the Middle East, particularly in Saudi Arabia. The agreement includes provisions for future expansion into other GLP products beyond the initial offerings, allowing for a broader spectrum of diabetes treatments. The partnership aims to deliver unique health solutions that enhance the well-being of patients in Saudi Arabia and surrounding areas, aligning with both companies’ commitment to improving healthcare access. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that markets both branded and generic pharmaceutical products.

Which Organizations Are Involved In The Branded Generics Market?

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Access The Complete Branded Generics Market Report:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Region Accounts For The Highest Share Of The Branded Generics Market?

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Branded Generics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Browse Through More Reports Similar to the Global Branded Generics Market 2026, By The Business Research Company

Branded Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Specialty Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Specialty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Are The Market Size Estimates For The Branded Generics Market In 2026 And 2030?

The size of the branded generics market has experienced rapid expansion in recent years. It is anticipated to increase from $393.5 billion in 2025 to $434.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. This historical expansion can be attributed to several factors, including the patent expirations of key drugs, the increasing acceptance of generic medications, rising healthcare expenditure, government support for generics, and the growing prevalence of chronic diseases.

The branded generics market size is anticipated to experience rapid growth in the next few years. It is projected to expand to $653.17 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.7%. The expected growth during this forecast period can be attributed to the expansion of branded generics portfolios, the adoption of digital marketing strategies in the pharmaceutical industry, an increase in partnerships with healthcare providers, the growth of emerging markets, and advancements in drug formulation technologies. Significant trends for the forecast period include enhanced brand awareness among patients, marketing strategies prioritizing differentiation, an increase in prescription volumes for branded generics, a growing preference for branded generics among physicians, and the continued expansion of emerging markets for generic drugs.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

What Primary Drivers Are Shaping The Branded Generics Market?

The growing incidence of chronic ailments is anticipated to propel the expansion of the branded generics market. These conditions are persistent illnesses that are frequently incurable but remain manageable and treatable. The rise in chronic diseases is attributed to factors such as increased tobacco consumption, inadequate nutrition, lack of physical activity, excessive alcohol intake, among others. Globally, consumers are leaning towards branded generics for managing chronic diseases, given their affordability compared to conventional drugs. For example, data from April 2025, from the US-based federal agency, the Centers for Disease Control and Prevention, revealed that in 2023, approximately 76.4% of U.S. adults disclosed experiencing at least one of 12 selected chronic conditions, while 51.4% reported having multiple chronic conditions. Consequently, the rising occurrence of chronic illnesses is fostering the expansion of the branded generics market.

How Is Segmentation Applied In The Branded Generics Market Segment Analysis?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

What Trends Are Affecting The Direction Of The Branded Generics Market?

Companies operating in branded generics are increasingly forming alliances with pertinent entities to leverage each other’s assets and expand into new markets. For example, in September 2024, Biocon Ltd., an India-based pharmaceutical company, collaborated with Tabuk Pharmaceuticals. Biocon will be responsible for the creation and production of GLP-1 products, guaranteeing premium biopharmaceuticals tailored for treating diabetes. Tabuk Pharmaceuticals will hold the marketing authorization rights and will oversee the registration, importation, and promotion of these products across the Middle East, with a specific emphasis on Saudi Arabia. The agreement also contains provisions for future growth into other GLP products beyond the initial range, allowing for a broader spectrum of diabetes treatments. This partnership aims to deliver distinctive health solutions that enhance the well-being of patients in Saudi Arabia and surrounding areas, aligning with both companies’ dedication to improving access to healthcare. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that markets both branded and generic pharmaceutical products.

Who Are The Companies Participating In The Branded Generics Market Environment?

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Get The Full Branded Generics Market Report:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Region Leads The Branded Generics Market In Overall Market Size?

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Branded Generics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Browse Through More Reports Similar to the Global Branded Generics Market 2026, By The Business Research Company

Branded Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Specialty Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Specialty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Will Be The Estimated Market Valuation Of The Branded Generics Market By The End Of 2030?

Recent years have witnessed substantial growth in the size of the branded generics market. This market is expected to expand, increasing from $393.5 billion in 2025 to $434.56 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. During the historic period, the growth was primarily due to several factors: patent expirations of key drugs, growing generic drug acceptance, rising healthcare expenditure, government support for generics, and increasing prevalence of chronic diseases.

The branded generics market size is projected to experience substantial expansion in the coming years. By 2030, its value is forecast to reach $653.17 billion, driven by a compound annual growth rate (CAGR) of 10.7%. Several elements will fuel this growth over the projected timeframe, such as an expanded portfolio of branded generics, the uptake of digital marketing in pharmaceuticals, stronger alliances with healthcare providers, market growth in developing regions, and innovations in drug formulation technologies. Prominent trends during the forecast period encompass greater patient awareness of brands, marketing initiatives centered on product differentiation, an uptick in branded generic prescriptions, enhanced physician endorsement of branded generics, and the continued development of emerging markets for generic drugs.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

What Primary Drivers Are Shaping The Development Of The Branded Generics Market?

The growing incidence of chronic diseases is anticipated to drive the expansion of the branded generics market. Chronic diseases are persistent illnesses that frequently lack a cure but can be managed and controlled. The rise in these conditions stems from increased tobacco product usage, poor dietary habits, lack of physical activity, excessive alcohol consumption, among other factors. Worldwide customers are increasingly choosing branded generics for the treatment of chronic diseases, owing to their lower cost compared to regular medications. For instance, in April 2025, figures from the Centers for Disease Control and Prevention, a US-based federal agency, showed that in 2023, around 76.4% of U.S. adults reported experiencing at least one of 12 selected chronic conditions, with 51.4% of U.S. adults reporting multiple chronic conditions. Therefore, the heightened prevalence of chronic diseases is accelerating the growth of the branded generics market.

Which Segment Classifications Shape The Branded Generics Market?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

How Are Trends Impacting The Branded Generics Market?

Leading companies in the branded generics sector are forming collaborations with suitable businesses to utilize shared resources and expand into novel markets. As an illustration, in September 2024, Biocon Ltd., an India-based pharmaceutical company, established a partnership with Tabuk Pharmaceuticals. Biocon will be in charge of developing and manufacturing the GLP-1 products, ensuring the delivery of high-quality biopharmaceuticals specifically formulated for diabetes treatment. Tabuk Pharmaceuticals will secure the marketing authorization rights and manage the registration, importation, and promotion of these products throughout the Middle East, with a particular focus on Saudi Arabia. The arrangement also includes provisions for future growth into other GLP products beyond the initial set, facilitating a more extensive array of diabetes treatments. This partnership aims to offer distinctive health solutions that uplift the well-being of patients in Saudi Arabia and neighboring territories, aligning with both companies’ commitment to bettering healthcare accessibility. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that distributes branded and generic pharmaceutical products.

Which Companies Are Expanding Their Footprint In The Branded Generics Market?

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Read the full branded generics market report here:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

How Does The Branded Generics Market Perform Across Major Global Regions?

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Branded Generics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Browse Through More Reports Similar to the Global Branded Generics Market 2026, By The Business Research Company

Branded Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Specialty Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Specialty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the branded generics market from 2026–2035 with trusted insights from The Business Research Company

What is the estimated market size of the Branded Generics Market by the end of 2030?

The branded generics market has experienced swift expansion recently. This market is projected to expand from $393.5 billion in 2025 to $434.56 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. Historically, this expansion can be linked to factors such as patent expirations of key drugs, increasing acceptance of generic drugs, a rise in healthcare spending, governmental backing for generics, and the growing prevalence of chronic diseases.

The branded generics market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $653.17 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.7%. This anticipated growth during the forecast period is driven by several factors, including the widening of branded generics product lines, the embrace of digital marketing within the pharmaceutical sector, an increase in collaborations with healthcare providers, the expansion into developing economies, and breakthroughs in drug formulation technologies. Key developments expected during this period encompass a rise in brand recognition among patients, marketing approaches emphasizing differentiation, an increase in prescriptions for branded generics, growing preference for branded generics among physicians, and the broadening of emerging markets for generic medications.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

What Drivers Are Shaping Future Opportunities In The Branded Generics Market?

The expansion of the branded generics market is anticipated, fueled by the rising occurrence of chronic diseases. These illnesses are persistent and, while frequently incurable, can be managed and controlled. Factors contributing to their increase include greater tobacco product consumption, inadequate nutrition, lack of physical activity, and excessive alcohol intake, among others. Globally, consumers show a preference for branded generics for managing chronic conditions, primarily because they offer a more economical alternative to conventional medicines. Illustratively, data from April 2025, provided by the Centers for Disease Control and Prevention, a US-based federal agency, indicated that in 2023, approximately 76.4% of U.S. adults disclosed having at least one of 12 selected chronic conditions, with 51.4% of U.S. adults reporting multiple chronic conditions. Consequently, the growing frequency of chronic diseases is a key factor propelling the branded generics market forward.

Which Segments Are Gaining Traction In The Branded Generics Market?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Which Competitive Trends Are Impacting The Structure Of The Branded Generics Market?

Leading firms in the branded generics sector are forming collaborations with pertinent entities to combine their assets and penetrate new territories. As an illustration, during September 2024, Biocon Ltd., an India-based pharmaceutical company, established a partnership with Tabuk Pharmaceuticals. Biocon is tasked with the creation and production of GLP-1 products, guaranteeing premium biopharmaceuticals specifically designed for managing diabetes. Tabuk Pharmaceuticals will possess the marketing authorization and will oversee the registration, import, and marketing of these offerings throughout the Middle East, with a particular focus on Saudi Arabia. This arrangement incorporates clauses for future expansion into additional GLP products beyond the initial range, enabling a wider array of diabetes therapies. The collaboration seeks to provide distinct health solutions that boost the welfare of patients in Saudi Arabia and neighboring regions, consistent with both organizations’ dedication to enhancing healthcare availability. Tabuk Pharmaceuticals is a pharmaceutical firm based in Saudi Arabia, distributing both branded and generic pharmaceutical goods.

Who Are The Core Companies Influencing Trends In The Branded Generics Market?

Major companies operating in the branded generics market are Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Regions Are Projected To Dominate The Branded Generics Market In The Coming Years?

North America was the largest region in the branded generics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Branded Generics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Browse Through More Reports Similar to the Global Branded Generics Market 2026, By The Business Research Company

Branded Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Specialty Generics Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Specialty Products Market Report 2026

https://www.thebusinessresearchcompany.com/report/specialty-products-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the branded generics market from 2025–2034 with trusted insights from The Business Research Company

What CAGR And Valuation Are Anticipated For The Branded Generics Market By The End Of 2029?

The branded generics market has seen significant expansion in recent years. This market is set to expand from $363.49 billion in 2024 to $393.5 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 8.3%. The historical increase can be ascribed to elements such as cost savings and affordability, patent expiries, market expansion and access, government initiatives and policies, and healthcare reforms.

The branded generics market size is anticipated to undergo swift expansion in the upcoming years. It is predicted to attain a value of $588.37 billion by 2029, achieving a compound annual growth rate (CAGR) of 10.6%. The expansion projected for the forecast period can be ascribed to factors such as the increasing demand for generic biologics, the prevalence of chronic diseases, the development of emerging markets, and an emphasis on biosimilars. Prominent trends identified for this period encompass strategic partnerships and collaborations, advancements in technology, a sustained focus on chronic diseases, market consolidation, and a patient-centric methodology.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

Which Business Drivers Are Underpinning The Growth Of The Branded Generics Market?

The rising occurrence of chronic illnesses is set to propel the expansion of the branded generics market. These are persistent health conditions that frequently lack a definitive cure but can be managed and kept in check. Their rise is attributed to factors such as increased tobacco consumption, inadequate diet, lack of physical activity, excessive alcohol intake, among other causes. Globally, consumers are leaning towards branded generics for chronic disease treatment, drawn by their affordability compared to standard pharmaceutical options. As an example, the World Health Organization (WHO) 2022 Highlights, published in September 2022 by the Switzerland-based intergovernmental health organization, reported 41 million deaths annually worldwide, accounting for 74% of all fatalities, due to noncommunicable diseases (NCDs) or chronic diseases. Consequently, the growing prevalence of chronic diseases is anticipated to significantly elevate the demand for branded generics throughout the forecast timeframe.

What Are The Principal Segment Types In The Branded Generics Market?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

How Are Industry Trends Steering The Expansion Of The Branded Generics Market?

Strategic alliances represent a key development in the branded generics market. Companies operating within this sector are establishing collaborations with relevant entities to leverage shared resources and expand into new markets. For example, in September 2024, Biocon Ltd., an India-based pharmaceutical company, formed a partnership with Tabuk Pharmaceuticals. Biocon will take charge of the development and manufacturing of GLP-1 products, guaranteeing premium biopharmaceuticals specifically designed for diabetes treatment. Tabuk Pharmaceuticals will possess the marketing authorization rights, managing the registration, importation, and promotion of these products across the Middle East, particularly within Saudi Arabia. The agreement also includes provisions for future expansion into other GLP products beyond the initial offerings, allowing for a broader spectrum of diabetes treatments. This partnership aims to deliver distinctive health solutions that enhance patient well-being in Saudi Arabia and surrounding areas, aligning with both companies’ commitment to improving healthcare access. Tabuk Pharmaceuticals is a Saudi Arabia-based pharmaceutical company that markets both branded and generic pharmaceutical products.

Which Companies Are Contributing Significantly To The Branded Generics Market Growth?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

Which Region Offers The Most Opportunity For Branded Generics Market Expansion?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

Browse Through More Reports Similar to the Global Branded Generics Market 2025, By The Business Research Company

Gastrointestinal Drug Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastrointestinal-drug-global-market-report

Nutritional Feed Additives Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/nutritional-feed-additives-global-market-report

Pharmacies And Drug Stores Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pharmacies-and-drug-stores-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What CAGR Is Anticipated for the Branded Generics Market Through 2029?

The market size for branded generics has seen significant growth in the past few years. Its expansion is projected to continue, rising from $363.49 billion in 2024 to $393.5 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 8.3%. Factors driving the growth during the historical period include affordability and cost savings, the expiration of patents, market outreach and expansion, government strategies and policies, as well as healthcare reforms.

It is anticipated that the branded generics market will experience swift expansion in the upcoming years. The projected growth suggests that the value will escalate to “$588.37 billion in 2029, with a compound annual growth rate (CAGR) of 10.6%.” This predicted acceleration during the forecast period can be attributed to the increased demand for generic biologics along with the surge in chronic diseases, burgeoning markets, and emphasis on biosimilars. The future trends observed include strategic alliances, technological evolutions, concentration on chronic ailments, consolidation of the market, and a patient-centric approach.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

What Market Forces Are Driving The Branded Generics Sector In 2025 And Beyond?

The rising incidence of chronic diseases are projected to fuel the expansion of the branded generics market. Chronic diseases, often incurable yet manageable, are persistent in nature. Increasing tobacco consumption, inadequate nutrition, lack of physical activity, and excessive alcohol intake are some factors contributing to the rise of chronic diseases. Globally, consumers prefer branded generics for treating chronic diseases due to their lower price compared to conventional medications. For example, in September 2022, the World Health Organization (WHO) 2022 Highlights reported that 74% of all deaths worldwide, equating to 41 million fatalities, resulted from noncommunicable diseases (NCDs) or chronic diseases. This upsurge in chronic diseases is anticipated to drive the demand for branded generics in the forecast period.

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Which Trends Are Redefining The Future Landscape Of The Branded Generics Industry?

Strategic alliances are a significant trend in the branded generics market. Firms in the branded generics domain are forming partnerships with corresponding companies to utilize their resources mutually and penetrate new markets. E.g., Biocon Ltd., an Indian pharmaceutical firm, collaborated with Tabuk Pharmaceuticals in September 2024. Biocon will undertake the development and production of GLP-1 items, guaranteeing top-tier biopharmaceuticals designed specifically for diabetes care. Tabuk Pharmaceuticals, on the other hand, will have marketing authorization and will oversee the registration, importation, and promotion of these products predominantly in Saudi Arabia. The agreement also comprises stipulations for further expansion into other GLP products beyond the initial offerings, enabling a wider spectrum of diabetes therapies. This collaboration is designed to deliver bespoke health solutions that elevate the health of patients in Saudi Arabia and nearby regions, complementing both firms’ devotion to augmenting healthcare accessibility. Based in Saudi Arabia, Tabuk Pharmaceuticals commercializes branded and generic pharmaceutical goods.

Which Firms Are Considered Leaders In The Branded Generics Market Space?

Major companies operating in the branded generics market include Pfizer Inc., F. Hoffmann-La Roche AG, Sanofi SA, AstraZeneca plc, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Alkem Laboratories Ltd., Mylan N.V., Sandoz International GmbH, Bausch Health Companies Inc., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Aurobindo Pharma Ltd., Dr. Reddy’s Laboratories Ltd., Apotex Inc., Aspen Pharmacare Holdings Limited, Endo International plc, Towa Pharmaceutical Co. Ltd., Mankind Pharma, Glenmark Pharmaceuticals, Par Pharmaceuticals Inc., Unichem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Wockhardt, Intas Pharmaceuticals Ltd., Novartis International AG, Novo Nordisk A/S, Zydus Lifesciences Ltd.

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

What Role Do Regional Policies And Investments Play In Branded Generics Market Expansion?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What is the Projected CAGR for the Branded Generics Market Size from 2025 to 2034?

In the last few years, the market size of branded generics has significantly expanded. It’s anticipated to surge from $363.49 billion in 2024 up to $393.5 billion in 2025, marking a compound annual growth rate (CAGR) of 8.3%. Factors contributing to this growth during the historic period include cost-effectiveness and affordability, expiration of patents, market expansion and accessibility, government policies and initiatives, as well as healthcare reforms.

The market size for branded generics is projected to experience swift expansion in the coming years, ballooning to $588.37 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 10.6%. Factors influencing the growth during this forecast period include an increased need for generic biologics, the prevalence of chronic diseases, emerging markets development, and emphasis on biosimilars. Key trends for this period encompass strategic alliances and collaborations, technological progression, focus on long-term illness, market amalgamation, and patient-centered approach.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=7186&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBranded Generics Market?

The branded generics market is set to grow due to the rising occurrence of chronic illnesses. These are enduring diseases which while not completely curable, can be managed effectively. The rise in chronic diseases can be attributed to factors such as increasing consumption of tobacco, poor diet, lack of physical exercise, high alcohol intake and other similar factors. Globally, consumers are gravitating towards branded generics for managing chronic illnesses as these are more financially viable compared to regular medications. For example, in the 2022 Highlights released by the World Health Organisation (WHO), a health agency based in Switzerland, in September 2022, it was reported that out of all global deaths, 74% or 41 million deaths are due to noncommunicable diseases (NCDs) or chronic illnesses, annually. Hence, the growing incidence of chronic illnesses is predicted to propel the demand for branded generics over the projected period.

Which Segments in the Branded Generics Offer the Most Growth?

The branded generics market covered in this report is segmented –

1) By Drug Class: Alkylating Agents, Antimetabolites, Hormones, Anti-Hypertensive, Lipid Lowering Drugs, Anti-Depressants, Anti-Psychotics, Anti-Epileptics, Other Drugs

2) By Route Of Administration: Topical, Oral, Parenteral, Other Routes Of Administration

3) By Application: Oncology, Cardiovascular Diseases, Diabetes, Neurology, Gastrointestinal Diseases, Dermatology Diseases, Analgesics And Anti-inflammatory, Other Applications

Subsegments:

1) By Alkylating Agents: Nitrogen Mustards, Ethylene Imine Compounds

2) By Antimetabolites: Purine Analogues, Pyrimidine Analogues

3) By Hormones: Corticosteroids, Thyroid Hormones

4) By Anti-Hypertensive: ACE Inhibitors, Beta Blockers, Calcium Channel Blockers

5) By Lipid Lowering Drugs: Statins, Fibrates

6) By Anti-Depressants: SSRIs (Selective Serotonin Reuptake Inhibitors), SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

7) By Anti-Psychotics: Atypical Antipsychotics, Typical Antipsychotics

8) By Anti-Epileptics: Sodium Channel Blockers, GABAergic Drugs

9) By Other Drugs: Analgesics, Antibiotics, Antivirals

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=7186&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theBranded Generics Market?# Market?

North America was the largest region in the branded generics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the branded generics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Branded Generics Industry?

Collaborative undertakings are emerging as a primary trend in the branded generics sector. Firms within this market are forming alliances with suitable partners to capitalize on each other’s assets and extend their reach into fresh territories. For instance, in September 2024, Biocon Ltd., an Indian pharmaceutical entity, established a partnership with Tabuk Pharmaceuticals. Biocon’s role will be in the production and development of GLP-1 products, ensuring top-notch biopharmaceuticals specifically designed for diabetes management. Tabuk Pharmaceuticals, on the other hand, will possess marketing authorization rights and will supervise the registration, import, and promotion of these offerings throughout the Middle East, primarily in Saudi Arabia. This deal also accommodates provisions for potential expansion into other GLP products beyond the initial offerings, enabling a wider spectrum of diabetes therapies. The aim of this alliance is to create distinctive health solutions to uplift patients’ health quality in Saudi Arabia and nearby regions, in line with the commitment of both companies towards enhancing healthcare accessibility. Tabuk Pharmaceuticals, headquartered in Saudi Arabia, deals in the marketing of branded and generic pharmaceutical goods.

View the full report here:

https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report

What Are the Key Elements That Define the Branded Generics Market?

Branded generics refer to an unregistered drug that is marketed under a brand name and provides patients and healthcare providers with a benefit that encourages them to choose the brand. These are the generic medications that have a unique brand name on the market. They might be advertised similarly to how branded medications are.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=7186

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model